LEADS BIOLABS-B Surges Over 7% in Morning Trading as Six Study Abstracts Highlight Differentiated Efficacy and Long-Tail Survival Edge

Deep News10-20

On the morning of trading, LEADS BIOLABS-B (HKEX: 09887) climbed more than 7%. As of the time of writing, the stock was up 6.59% at HK$44.02, with turnover of HK$23.3259 million.

On October 19, LEADS BIOLABS-B announced that full abstracts of six studies on its independently developed Virexer® (opapatsumib, an anti-PD-L1/4-1BB bispecific antibody) and LBL-034 (a GPRC5D/CD3 bispecific T-cell engager, or TCE) have been published on the official website of the 2026 ESMO Annual Meeting.

The data collectively demonstrate Virexer®'s trend of durable responses and long-tail survival benefits across multiple immune "cold tumors," supporting its potential as a pan-tumor therapy and underscoring the company's differentiated capabilities across its X-body and TCE technology platforms.

Notably, three studies on Virexer® and LBL-034 were selected for preferred oral presentations at the 2026 ESMO, with one study chosen as a Late-Breaking Abstract (LBA). Detailed and updated data from these studies will be released during the oral presentation sessions at the 2026 ESMO.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment